Module 3 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies
Visit https://annenberg.net/Atopic-Dermatitis-Therapy-CME to download resources, view more videos and earn CME credit.
Lawrence F. Eichenfield, MD, and Jonathan Silverberg, MD, PhD, MPH, provide their perspectives on the clinical impact of 6 recently published studies involving the management of patients with atopic dermatitis.
This module discusses "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis" by Dr. Simpson and colleagues. The study results appeared in the December 15, 2016, issue of The New England Journal of Medicine.
Видео Module 3 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies канала Annenberg Center for Health Sciences
Lawrence F. Eichenfield, MD, and Jonathan Silverberg, MD, PhD, MPH, provide their perspectives on the clinical impact of 6 recently published studies involving the management of patients with atopic dermatitis.
This module discusses "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis" by Dr. Simpson and colleagues. The study results appeared in the December 15, 2016, issue of The New England Journal of Medicine.
Видео Module 3 - Expert Analysis of Emerging Atopic Dermatitis Therapy Studies канала Annenberg Center for Health Sciences
Показать
Комментарии отсутствуют
Информация о видео
3 мая 2017 г. 22:41:07
00:09:59
Другие видео канала
Clinical Cases in Interstitial Lung Disease - Case 2
Palliative Care: Pulmonary Rehabilitation - Interstitial Lung Disease: Altering the Disease Course
Melanoma: Updates from Brisbane, Australia (Abstract 4, Question 1)
Evaluation and Diagnosis: Diagnostic Algorithm for IPF - Interstitial Lung Disease
Treatment of Moderate-Severe Atopic Dermatitis: Overview
Track 2 Stop 5 organ threatening disease - Systemic Lupus Erythematosus
The New Paradigm in Atopic Dermatitis Treatment: Line 1 Stop 3 Disease Assessment
The New Paradigm in Atopic Dermatitis Treatment: Line 2 Stop 5 Osteoporosis
Future Directions: Telomere - Interstitial Lung Disease: Altering the Disease Course
Treatment of Moderate-Severe Atopic Dermatitis: Line 7 Stop 3 Clinical Efficacy
Understanding Biosimilars: Differences Between Biosimilars and Reference Products
Managing Challenges with Traditional Treatments: Polycythemia Vera
Treating Acute Exacerbations: Is It an Exacerbation? - Interstitial Lung Disease
The New Paradigm in Atopic Dermatitis Treatment: Line 6 Stop 3 Topical Calcineurin Inhibitors
Treatment Options (Track T Stop 2) IPF: Navigating a Complex Disease
Introduction - Combination Basal Insulin + GLP-1RA Therapy
Diagnosis Algorithm (Track H Stop 9) IPF: Navigating a Complex Disease
Future Directions: Clinical Trial Overview - Interstitial Lung Disease: Altering the Disease Course
Treatment of Moderate-Severe Atopic Dermatitis: Line 4 Stop 4 Adherence
Future Directions: IPF Net- Interstitial Lung Disease: Altering the Disease Course